title: Effects of zoledronic acid on odontoblast-like cells.
abstract: The aim of the study was to evaluate the effects of a highly potent bisphosphonate, zoledronic acid (ZOL), on cultured odontoblast-like cells MDPC-23. The cells (1.5×10(4)cells/cm(2)) were seeded for 48h in wells of 24-well dished. Then, the plain culture medium (DMEM) was replaced by fresh medium without fetal bovine serum. After 24h, ZOL (1 or 5μM) was added to the medium and maintained in contact with the cells for 24h. After this period, the succinic dehydrogenase (SDH) enzyme production (cell viability - MTT assay), total protein (TP) production, alkaline phosphatase (ALP) activity, and gene expression (qPCR) of collagen type I (Col-I) and ALP were evaluated. Cell morphology was assessed by SEM. Five μM ZOL caused a significant decrease in SDH production. Both ZOL concentrations caused a dose-dependent significant decrease in TP production and ALP activity. ZOL also produced discret morphological alterations in the MDPC-23 cells. Regarding gene expression, 1μM ZOL caused a significant increase in Col-I expression. Although 5μM ZOL did not affect Col-I expression, it caused a significant alteration in ALP expression (ANOVA and Tukey's test, p<0.05). ZOL presented a dose-dependent cytotoxic effect on the odontoblast-like cells, suggesting that under clinical conditions the release of this drug from dentin could cause damage to the pulpo-dentin complex.
authors.affiliation: UNICAMP - Universidade de Campinas, Piracicaba School of Dentistry, Piracicaba, SP, 13414-903, Brazil.
authors.forename: F G
authors.initials: FG
authors.lastname: Basso
authors.forename: A P S
authors.initials: AP
authors.lastname: Turrioni
authors.forename: J
authors.initials: J
authors.lastname: Hebling
authors.forename: C A
authors.initials: CA
authors.lastname: de Souza Costa
mesh_terms: D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000037:antagonists & inhibitors; D004164:Diphosphonates / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D016326:Extracellular Matrix Proteins / Q000037:antagonists & inhibitors; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000633:toxicity*; D009804:Odontoblasts / Q000187:drug effects*; D010750:Phosphoproteins / Q000037:antagonists & inhibitors; D011500:Protein Synthesis Inhibitors / Q000633:toxicity; D012795:Sialoglycoproteins / Q000037:antagonists & inhibitors; D013385:Succinate Dehydrogenase / Q000096:biosynthesis; D000077211:Zoledronic Acid; D000099311:Dentin Sialophosphoprotein
chemical_list: D000469:Alkaline Phosphatase; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D016326:Extracellular Matrix Proteins; D007093:Imidazoles; D010750:Phosphoproteins; D011500:Protein Synthesis Inhibitors; D012795:Sialoglycoproteins; D013385:Succinate Dehydrogenase; D000077211:Zoledronic Acid; D000099311:Dentin Sialophosphoprotein